2024-03-28T09:08:14Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_09E73A101B01
2024-03-23T01:49:39Z
serval:BIB_09E73A101B01
Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
10.1016/j.eururo.2018.06.045
000446875700014
30033046
Chevalier
M.F.
author
Schneider
A.K.
author
Cesson
V.
author
Dartiguenave
F.
author
Lucca
I.
author
Jichlinski
P.
author
Nardelli-Haefliger
D.
author
Derré
L.
author
article
2018-11
European urology
1873-7560
0302-2838
journal
74
5
540-544
Administration, Intravesical
B7-H1 Antigen/immunology
BCG Vaccine/administration & dosage
BCG Vaccine/adverse effects
CD4 Lymphocyte Count
Case-Control Studies
Cell Line, Tumor
Coculture Techniques
Humans
Prospective Studies
T-Lymphocytes, Regulatory/immunology
T-Lymphocytes, Regulatory/pathology
Time Factors
Treatment Outcome
Urinary Bladder Neoplasms/immunology
Urinary Bladder Neoplasms/pathology
Urinary Bladder Neoplasms/therapy
Urinary Bladder Neoplasms/urine
Urine/cytology
Urothelium/immunology
Urothelium/pathology
BCG therapy
Immune checkpoint
Immunoregulation
PD-L1
Tregs
Urothelial cancer
eng
60_published
peer-reviewed
Publication types: Letter ; Research Support, Non-U.S. Gov't
Publication Status: ppublish